Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoff Hale

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
Arthritis and Rheumatism|February 2, 2008
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomesAlice R Lorenzi, Alexandra M Clarke, Tom Wooldridge, et al.
British Journal of Haematology|April 3, 2003
T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survivalSuparno Chakrabarti, Dorothy MacDonald, Geoff Hale, et al.
The Journal of Infectious Diseases|August 10, 2006
A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivoTanzina Haque, Ingolfur Johannessen, Dilani Dombagoda, et al.
Haematologica|October 18, 2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapyAndy C Rawstron, Giles Laycock-Brown, Geoff Hale, et al.
Investigative Ophthalmology & Visual Science|December 24, 2003
Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammationKathrin Greiner, Conor C Murphy, Francois Willermain, et al.
British Journal of Haematology|October 9, 2003
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusionsShirley D'Sa, Karl Peggs, Arnold Pizzey, et al.
European Journal of Immunology|October 19, 2005
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosisAmanda L Cox, Sara A J Thompson, Joanne L Jones, et al.
Blood|July 20, 2002
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Jeanette Lundin, Eva Kimby, Magnus Björkholm, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|June 16, 2004
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitisConor C Murphy, Kathrin Greiner, Jarka Plskova, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
Arthritis and Rheumatism|February 2, 2008
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomesAlice R Lorenzi, Alexandra M Clarke, Tom Wooldridge, et al.
British Journal of Haematology|April 3, 2003
T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survivalSuparno Chakrabarti, Dorothy MacDonald, Geoff Hale, et al.
The Journal of Infectious Diseases|August 10, 2006
A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivoTanzina Haque, Ingolfur Johannessen, Dilani Dombagoda, et al.
Haematologica|October 18, 2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapyAndy C Rawstron, Giles Laycock-Brown, Geoff Hale, et al.
Investigative Ophthalmology & Visual Science|December 24, 2003
Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammationKathrin Greiner, Conor C Murphy, Francois Willermain, et al.
British Journal of Haematology|October 9, 2003
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusionsShirley D'Sa, Karl Peggs, Arnold Pizzey, et al.
European Journal of Immunology|October 19, 2005
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosisAmanda L Cox, Sara A J Thompson, Joanne L Jones, et al.
Blood|July 20, 2002
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Jeanette Lundin, Eva Kimby, Magnus Björkholm, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|June 16, 2004
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitisConor C Murphy, Kathrin Greiner, Jarka Plskova, et al.
Pageof 6